Statute Details
- Title: Health Products (Licensing of Retail Pharmacies) Regulations 2016
- Act Code: HPA2007-S330-2016
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (HSA) with Minister for Health approval
- Commencement: 1 November 2016
- Current Version: Current version as at 27 March 2026 (with amendments including S 692/2024 effective 4 September 2024)
- Key Provisions (as reflected in the extract): Definitions (reg. 2); retail supply requirements (reg. 3); telepharmacy services (reg. 4); application for pharmacy licence (reg. 5); suspension/revocation and cancellation (reg. 6); changes affecting licence (reg. 7); routine inspections (reg. 8); specified health products (First Schedule)
- Schedules: First Schedule (Specified health products); Second Schedule (Repealed)
What Is This Legislation About?
The Health Products (Licensing of Retail Pharmacies) Regulations 2016 (“Retail Pharmacies Regulations”) set out the regulatory framework for carrying on a retail pharmacy business in Singapore and for supplying certain regulated health products to the public. In plain terms, the Regulations require that if a person wants to supply “specified health products” by retail sale, that person must hold a pharmacy licence and comply with strict operational, record-keeping, and access-control requirements.
The Regulations also address modern dispensing models, including telepharmacy services, where a qualified pharmacist provides retail pharmacy services through computer or video/audio links. This is important for practitioners because it creates a legally defined pathway for remote pharmacy operations, while still imposing safeguards around who can access products and how supplies are documented.
Overall, the Regulations operationalise the Health Products Act’s licensing and public-safety objectives by prescribing the conditions under which retail pharmacies may supply specified health products, how licences are applied for and maintained, and how the Health Sciences Authority (HSA) monitors compliance through inspections and enforcement actions.
What Are the Key Provisions?
1. Definitions and regulatory scope (Regulation 2)
The Regulations contain a detailed set of definitions that control how the licensing and supply rules apply. For legal interpretation, the most important defined terms include:
- “pharmacy licence”: a licence issued by HSA to carry on a retail pharmacy business at or from the retail pharmacy specified in the licence.
- “retail pharmacy” and “retail pharmacy business”: premises (excluding a “pharmacy department”) from which retail pharmacy services are provided to the general public.
- “retail pharmacy services”: sale or dispensing of one or more specified health products, whether or not accompanied by advice or counselling.
- “specified health product”: a health product listed in the First Schedule.
- “in-store pharmaceutical officer” and “qualified pharmacist”: key roles controlling access to products and dispensing/supply activities.
- “telepharmacy services”: retail pharmacy services provided by a qualified pharmacist at a retail pharmacy through a computer or video/audio link.
These definitions matter because they determine who is permitted to do what, where, and under what conditions. For example, the Regulations distinguish between access to non-controlled products (other than controlled drugs) and access to controlled drugs, which are subject to heightened controls.
2. Core prohibition and conditions for retail supply (Regulation 3)
Regulation 3 is the heart of the licensing regime. It provides that, for the purposes of section 17 of the Health Products Act, a person must not supply by retail sale any specified health product unless all statutory conditions are met.
In summary, the conditions include:
- Licence requirement: the person must be the holder of a pharmacy licence.
- Supply must occur at the licensed premises: supply must be carried out at or from the retail pharmacy specified in the licence.
- Authorised personnel: supply must be carried out by an in-store pharmaceutical officer, or (in the absence of that officer) by a special mode with prior approval of HSA.
- Compliance with licence conditions: supply must be under and in accordance with the conditions of the pharmacy licence.
- Record-keeping: a proper record of every supply must be made by the in-store pharmaceutical officer (or using the approved special mode).
- Retention period: records must be kept for at least 2 years after the date of supply.
- Access control for stored products: only an in-store pharmaceutical officer may have access to specified health products stored at the retail pharmacy (other than controlled drugs).
- Access control for controlled drugs: only a qualified pharmacist may have access to any controlled drug stored at the retail pharmacy.
For practitioners, the practical legal significance is that Regulation 3 creates a structured compliance checklist. Non-compliance is not merely a breach of “good practice”; it goes to the legality of the supply itself. If the pharmacy supplies specified health products without meeting these conditions, the conduct may fall foul of the prohibition in section 17 of the Health Products Act as implemented by these Regulations.
3. Prescription-only medicines and additional safeguards
The extract indicates that Regulation 3(2) imposes further restrictions for prescription-only medicines. While the provided text is truncated, the structure is clear: beyond the general conditions for specified health products, prescription-only medicines may only be supplied in accordance with a valid prescription and the applicable procedural requirements.
In practice, this means that pharmacies must ensure that:
- the prescription is valid and properly documented; and
- the supply is carried out in accordance with the prescription and any licence conditions.
For lawyers advising retail pharmacy operators, the key issue is evidential: the pharmacy’s records and processes must be capable of demonstrating compliance with prescription requirements, not just the fact that a product was supplied.
4. Telepharmacy services (Regulation 4)
The Regulations also contemplate telepharmacy, defining it as the provision of retail pharmacy services by a qualified pharmacist at a retail pharmacy through a computer or video/audio link. Although the extract does not reproduce the full operative text of Regulation 4, the inclusion of telepharmacy in the Regulations signals that HSA has created a regulated pathway for remote pharmacy service delivery.
From a compliance perspective, telepharmacy typically raises questions about:
- how the pharmacist verifies orders and prescriptions;
- how the pharmacy ensures secure handling of specified health products; and
- how records are created and retained to demonstrate lawful supply.
Practitioners should therefore treat telepharmacy not as a “technology add-on”, but as a legally defined service model that must still satisfy the Regulation 3 conditions (licence, authorised access, and record-keeping) and any additional telepharmacy-specific requirements.
5. Licensing lifecycle and enforcement (Regulations 5 to 7)
The Regulations provide for:
- Application for a pharmacy licence (Regulation 5): the process and requirements for obtaining a licence, including payment of an application fee (defined by reference to the Health Products (Fees) Regulations 2022).
- Suspension and revocation; cancellation of approval (Regulation 6): HSA’s enforcement powers where compliance is not maintained.
- Changes affecting the pharmacy licence (Regulation 7): obligations to notify or obtain approval where relevant circumstances change (for example, changes to premises, personnel, or service arrangements).
These provisions are crucial for operators and their counsel because they govern risk management. A pharmacy’s legal exposure is not limited to day-to-day supply practices; it also includes how the licence is maintained and whether changes trigger regulatory notification or approval.
6. Routine inspections (Regulation 8)
Regulation 8 states that the Authority may conduct routine inspections of any retail pharmacy to ensure compliance with the provisions of the Regulations. This inspection power is a key enforcement mechanism. Practically, it means pharmacies should maintain audit-ready documentation—particularly supply records and evidence of controlled access to specified health products and controlled drugs.
How Is This Legislation Structured?
The Regulations are structured as follows:
- Part/Regulation 1: Citation and commencement (1 November 2016).
- Regulation 2: Definitions (sets the interpretive framework).
- Regulation 3: Requirements for supply by retail sale of specified health products (core compliance obligations).
- Regulation 4: Telepharmacy services (remote service delivery framework).
- Regulation 5: Application for pharmacy licence (licensing process).
- Regulation 6: Suspension and revocation of pharmacy licence and cancellation of approval (enforcement powers).
- Regulation 7: Changes affecting pharmacy licence (ongoing compliance and notification/approval duties).
- Regulation 8: Routine inspections (monitoring and compliance verification).
- Regulation 9: Deleted (as indicated in the enacting formula).
- First Schedule: Specified health products (the list that determines what triggers the licensing and supply regime).
- Second Schedule: Repealed (historical or transitional provisions).
Who Does This Legislation Apply To?
The Regulations apply primarily to persons who carry on, or intend to carry on, a retail pharmacy business in Singapore and who supply specified health products by retail sale. In practical terms, this includes pharmacy operators and licence holders, as well as the pharmacists and other authorised personnel who perform or supervise supply activities.
The Regulations also apply to service models involving telepharmacy services, where a qualified pharmacist provides retail pharmacy services through remote communication links. Even where services are delivered remotely, the legal obligations around licensing, authorised access, and record-keeping remain central.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they translate the Health Products Act’s broad public-safety objectives into concrete operational requirements. The prohibition in Regulation 3 is framed as a condition for lawful supply: if the pharmacy does not meet the licensing, personnel, access, and record-keeping requirements, the supply may be unlawful.
From a compliance and enforcement perspective, the Regulations create multiple “control points” that regulators can test during inspections: whether the pharmacy holds a licence; whether supply is conducted at the licensed premises; whether only authorised personnel access specified health products and controlled drugs; and whether records are properly made and retained for at least two years. This makes the Regulations highly relevant to counsel advising on pharmacy governance, internal controls, and audit readiness.
Finally, the telepharmacy provisions reflect Singapore’s regulatory approach to innovation: remote delivery is permitted, but only within a defined legal framework. Lawyers should therefore consider these Regulations when advising on technology-enabled pharmacy models, ensuring that remote workflows still satisfy the same legal safeguards as in-person dispensing.
Related Legislation
- Health Products Act (Cap. 122D)
- Drugs Act 1973
- Healthcare Services Act 2020
- Healthcare Services (Collaborative Prescribing Service) Regulations 2023
- Pharmacists Registration Act 2007
- Pharmacists Registration (Practising Certificates) Regulations 2008
- Dental Registration Act 1999
- Health Products (Fees) Regulations 2022
Source Documents
This article provides an overview of the Health Products (Licensing of Retail Pharmacies) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.